Emergent Biosolutions (EBS) : Tuesdays money flow analysis of Emergent Biosolutions (EBS) indicates the selling of stock on the strength of price. The investors sold the stock on every rise as seen in the downtick transactions of $6.04 million. In comparison, the inflow of money on upticks was a meager $2.37 million. The dollar value of composite uptick trades minus the downtick trades was negative $3.68 million. The uptick to downtick ratio of 0.39 in the money flow shows weakness. The downtick transaction value was high at $4.01 million, which denotes distribution on strength.. Hence, the net money flow in the stock was negative ($4.01 million). Emergent Biosolutions (EBS) gained $1.18 at $31.65, a change of 3.87% over the previous days close.
The company Insiders own 17.2% of Emergent Biosolutions shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -6.63% . Institutional Investors own 84.13% of Emergent Biosolutions shares. During last six month period, the net percent change held by insiders has seen a change of -9.37%. In an insider trading activity,The director of Emergent Biosolutions Inc., Joulwan George A sold 4,700 shares at $44.12 on June 6, 2016. The Insider selling transaction had a total value worth of $207,364. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Shares of Emergent BioSolutions, Inc. appreciated by 9.49% during the last five trading days but lost 25.51% on a 4-week basis. Emergent BioSolutions, Inc. has dropped 18.58% during the last 3-month period . Year-to-Date the stock performance stands at -21.24%.
Emergent Biosolutions (NYSE:EBS): stock turned positive on Tuesday. Though the stock opened at $30.76, the bulls momentum made the stock top out at $31.79 level for the day. The stock recorded a low of $30.76 and closed the trading day at $31.51, in the green by 3.41%. The total traded volume for the day was 751,649. The stock had closed at $30.47 in the previous days trading.
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Companys two operating divisions include Biodefense and Biosciences. The Companys Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical, Biological, Radiological, Nuclear and Explosives) threats. The Biodefense divisions marketed products are BioThrax; BAT; Anthrasil; VIGIV, and RSDL. The Biodefense division investigational stage product candidates include NuThrax, PreviThrax, GC-072 and other biodefense product candidates. The Biosciences divisions marketed products are WinRho SDF, HepaGam B, VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY, ES414 and otlertuzumab.